Safety and Efficacy of Autologous Transplantation of iPSC-RPE in the Treatment of Macular Degeneration

Inclusion Criteria:

• Aged 50-75 years;
• Clinical diagnosis is consistent with the definition of late dry AMD in theage-related eye disease study (AREDS), with one or more >250 um geographic atrophy inthe fovea;
• Clinical diagnosis is wet AMD, but no obvious efficacy after conventional treatment;
• The BCVA of the target eye will be 0.05 to 0.3;
• Voluntary as test subjects, informed consent, regular follow-up on time.

Exclusion Criteria:

• One-eyed subjects;
• Macular atrophy caused by other diseases in addition to AMD;
• Suffer from retinitis pigmentosa, choroidal retinitis, central serous choroiditis,diabetic retinopathy, or other retinal vascular and degenerative diseases besides AMD;
• Lens opacities (affecting the central vision), glaucoma, uveitis, retinal detachment,optic neuropathy, and other ocular histories;
• Other intraocular surgery histories besides cataract surgery;
• Combined with severe systemic diseases, such as heart failure, liver disease, renalinsufficiency, cor pulmonale, COPD in the previous 12 months;
• Combined with severe infectious diseases, such as HIV, HBV, HCV, syphilis,tuberculosis, etc;
• Abnormal blood coagulation function or other laboratory tests;
• If female and of childbearing potential, pregnant, breastfeeding, or planning tobecome pregnant through the study;
• If male, refuse to use barrier and spermicide contraception during the study;
• Malignant tumor and history of malignancy;
• Any immune deficiency;
• Allergy to tacrolimus or other macrolides;
• Any immune deficiency;
• Use glucocorticoids, immunosuppressive drugs, or antipsychotic drugs in the previous 3months;
• Use anticoagulant, or the platelet function is still not restored to normal afterstopping antiplatelet drugs for 10 days;
• A history of addiction to alcoholism or prohibited drugs;
• Be participating in other intervention clinical trials or receiving other studymedications;
• Poor compliance, difficulty to complete the study, or refusal to informed consent;
• Some other situations which might increase the risks of the subjects or interfere withclinical trials, such as mental disorders, cognitive dysfunction, etc.